1242087-97-3

Basic information

• Product Name: C₄₁H₄₂N₆O₄
• Synonyms: C₄₁H₄₂N₆O₄
• CAS NO: 1242087-97-3
• Molecular Weight: 682.822
• Mol File: 1242087-97-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₄₁H₄₂N₆O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₁H₄₂N₆O₄(1242087-97-3)
• EPA Substance Registry System: C₄₁H₄₂N₆O₄(1242087-97-3)

Safety Data

• Hazardous Substances Data: 1242087-97-3(Hazardous Substances Data)

Upstream product

• 1031747-33-7 (S)-2-[5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-benzoimidazol-2-yl]pyrrolidine-1-carboxylic acid benzyl ester 
• 1228551-96-9 1,1-dimethylethyl (2S)-2-[4-(6-bromo-2-naphthalenyl)-1H-imidazol-2-yl]-1-pyrrolidinecarboxylate 
• 1031747-50-8 (S)-2-(5-bromo-1H-benzoimidazol-2-yl)pyrrolidine-1-carboxylic acid benzyl ester 
• 1303533-76-7 2,2-dibromo-1-(6-bromonaphthalen-2-yl)ethanone 
• 50637-83-7 2-bromo-1-(6-bromonaphthalen-2-yl)ethanone 
• 861880-64-0 6-bromo-N-methoxy-N-methyl-2-naphthamide 
• 1228551-96-9 (S)-tert-butyl 2-(5-(6-bromonaphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 5773-80-8 6-bromo-2-naphthoic acid 
• 1590-25-6 1-(6-bromonaphthalen-2-yl)ethanone 
• 1031747-50-8 2-(6-bromo-1H-benzoimidazol-2-yl)pyrrolidine-1-carboxylic acid benzyl ester 
• 1228552-26-8 (S)-tert-butyl 2-(5-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 580-13-2 2-bromonaphthalene 
• 87700-60-5 6-bromonaphthalene-2-carbonyl chloride 

Relevant articles and documents

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.